Biotest Future Growth

Future criteria checks 4/6

Biotest is forecast to grow earnings and revenue by 82.7% and 6% per annum respectively while EPS is expected to grow by 76.5% per annum.

Key information

82.7%

Earnings growth rate

76.5%

EPS growth rate

Biotechs earnings growth	43.0%
Revenue growth rate	6.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	09 Sep 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:BIO - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	712	59	N/A	N/A	1
12/31/2024	636	-4	N/A	N/A	1
9/30/2024	679	41	56	90	N/A
6/30/2024	781	164	86	119	N/A
3/31/2024	783	177	-10	23	N/A
12/31/2023	685	127	-36	-3	N/A
9/30/2023	683	119	-122	-93	N/A
6/30/2023	538	-10	-146	-117	N/A
3/31/2023	517	-47	-127	-98	N/A
12/31/2022	516	-32	-70	-40	N/A
9/30/2022	505	-69	-4	14	N/A
6/30/2022	511	-65	30	49	N/A
3/31/2022	512	-54	51	69	N/A
12/31/2021	516	-63	16	34	N/A
9/30/2021	514	-28	-3	24	N/A
6/30/2021	507	-33	-32	-5	N/A
3/31/2021	507	-35	-49	-22	N/A
12/31/2020	484	-31	-44	-17	N/A
9/30/2020	466	-34	-74	-40	N/A
6/30/2020	459	-24	-83	-49	N/A
3/31/2020	439	-15	-70	-36	N/A
12/31/2019	419	-5	-68	-34	N/A
9/30/2019	406	-9	-74	-19	N/A
6/30/2019	395	-3	-61	-6	N/A
3/31/2019	390	-6	-81	-26	N/A
12/31/2018	400	-13	-105	-50	N/A
9/30/2018	405	18	-123	-16	N/A
6/30/2018	409	6	N/A	6	N/A
3/31/2018	400	1	N/A	15	N/A
12/31/2017	378	-16	N/A	34	N/A
9/30/2017	257	-48	N/A	8	N/A
6/30/2017	301	-47	N/A	-8	N/A
3/31/2017	340	-29	N/A	35	N/A
12/31/2016	408	6	N/A	66	N/A
9/30/2016	531	128	N/A	51	N/A
6/30/2016	525	52	N/A	57	N/A
3/31/2016	526	36	N/A	44	N/A
12/31/2015	535	27	N/A	38	N/A
9/30/2015	590	-88	N/A	62	N/A
6/30/2015	606	3	N/A	54	N/A
3/31/2015	602	16	N/A	15	N/A
12/31/2014	582	19	N/A	-11	N/A
9/30/2014	543	27	N/A	-26	N/A
6/30/2014	522	31	N/A	-28	N/A
3/31/2014	504	30	N/A	-1	N/A
12/31/2013	501	32	N/A	-7	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIO's forecast earnings growth (82.7% per year) is above the savings rate (1%).

Earnings vs Market: BIO's earnings (82.7% per year) are forecast to grow faster than the German market (21% per year).

High Growth Earnings: BIO's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BIO's revenue (6% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: BIO's revenue (6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BIO's Return on Equity is forecast to be high in 3 years time

Biotest Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023

Biotest AG Provides Earnings Guidance for the Year 2021

Biotest Aktiengesellschaft Provides Earnings Guidance for the Year 2021

Biotest AG Revised Earnings Guidance for the Fiscal Year 2020

Recent updates

Biotest Aktiengesellschaft to Report Fiscal Year 2024 Results on Mar 28, 2025

Biotest Aktiengesellschaft to Report Q2, 2024 Results on Aug 06, 2024

Biotest Receives FDA Approval for Innovative Yimmugo Immunoglobulin to Treat Primary Immunodeficiencies

Biotest Aktiengesellschaft, Annual General Meeting, May 07, 2024

Biotest Aktiengesellschaft to Report First Half, 2024 Results on Jul 30, 2024

Biotest Aktiengesellschaft to Report Fiscal Year 2023 Results on Mar 28, 2024

Biotest Aktiengesellschaft Raises Earnings Guidance for the Year 2023

Biotest AG Appoints Peter Janssen as Chairman of the Management Board, Effective from January 1, 2024

Biotest Treats First Patient with Severe Community- Acquired Pneumonia in Phase III Trial with Trimodulin

Biotest AG Announces US Food and Drug Administration Accepts Marketing Authorization Application for Immunoglobulin Yimmugo

Biotest AG Appoints Ainhoa Mendizabal as CFO, with Effect from 15 February, 2023

Biotest Aktiengesellschaft to Report Fiscal Year 2022 Results on Mar 23, 2023

Biotest AG Conducts Clinical Phase III Study PreCyssion with Cmv Hyperimmunoglobulin (Cytotect CP Biotest-) for the Prevention of CMV Infection in the Unborn Child in Germany

Biotest AG Achieves Important Milestone in Phase III Study in Acquired Fibrinogen Deficiency

Biotest AG Announces Board Changes

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Biotest Submits Marketing Authorisation Application for IgG Next Generation

Biotest AG Announces Biotest Treats First CMV-Positive Pregnant Woman in Phase III Clinical Trial to Prevent Transmission of CMV Infection to the Unborn Child

Biotest AG Accelerates Trimodulin Development in Hospitalized Covid-19 Patients with Federal Funding from the German Ministries of Health, and Education & Research

Biotest Receives Approval for Phase III Clinical Trial in Pregnant Women for Prevention of CMV Infection of the Unborn Baby

Biotest Announces the Outcome for Its ESsCOVID (Escape from Severe COVID-19) Trial in Patients with Severe COVID-19

Biotest AG Provides Earnings Guidance for the Year 2021

Biotest AG Successfully Completes Recruitment for Its Clinical Trial with Trimodulin in Severe Covid-19 Patients

Biotest Aktiengesellschaft Provides Earnings Guidance for the Year 2021

Biotest AG Supports Clinical Study with Pentaglobin(R) in Covid-19 at the University Hospital Akh Vienna

Biotest AG Revised Earnings Guidance for the Fiscal Year 2020

Biotest Aktiengesellschaft to Report Fiscal Year 2020 Results on Mar 31, 2021

Biotest Aktiengesellschaft Announces Approval of Biotest Aktiengesellschaft for the Treatment of Severe Bacterial Infections with Concomitant Use of Antibiotics

Biotest Aktiengesellschaft to Report Q1, 2021 Results on May 11, 2021

Biotest Aktiengesellschaft to Report Q2, 2020 Results on Aug 13, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies